Ankündigung • Mar 17
JS Link, Inc., Annual General Meeting, Mar 31, 2026 JS Link, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 31, magokjungang 8-ro 3-gil, gangseo-gu, seoul South Korea Ankündigung • Feb 04
JS Link, Inc. announced that it has received KRW 20.00000805 billion in funding from Orbitech Co., Ltd., Joosung Sea & Air Co. Ltd On February 3, 2026, JS Link, Inc closed the transaction. New Risk • Nov 29
New major risk - Revenue and earnings growth Earnings have declined by 0.01% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.01% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Ankündigung • Oct 30
JS Link, Inc. announced that it has received KRW 20.000005568 billion in funding from B & P Joosung Corp. On October 29, 2025, the JS Link, Inc closed the transaction. Ankündigung • Sep 23
JS Link, Inc. announced that it expects to receive KRW 12 billion in funding JS Link, Inc. announces a private placement with Rare Earth Mobility Fund to issue Bearer, unsecured, privately issued convertible bonds for gross proceeds of KRW 12,000,000,000 on September 22, 2025. Maturity date of the Notes is October 2, 2028. Interest rate of the Notes is 2%. and Expected closing date of the Notes is October 2, 2025. conversion price of the Notes is KRW 22,232. New Risk • Sep 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Ankündigung • Sep 17
JS Link, Inc. announced that it expects to receive KRW 20.00000805 billion in funding JS Link, Inc. announced a private placement to issue 1,308,045 common shares at an issue price of KRW 15,290 for gross proceeds of KRW 20,000,008,050 on September 15, 2025. The transaction includes participation from individual investor, Park Jin-soo. The transaction has been approved by the board of directors of the company. The payment date of the transaction is January 30, 2026. The transaction is subject to restrictions period of one year. Ankündigung • Sep 03
JS Link, Inc. announced that it has received KRW 7 billion in funding On September 3, 2025, JS Link, Inc. closed the transaction. Ankündigung • Aug 07
JS Link, Inc. announced that it expects to receive KRW 8 billion in funding JS Link, Inc. announced a private placement to issue 2% Series 15 Unregistered Interest Unsecured Private Convertible Bonds due September 3, 2028 for gross proceeds of KRW 8,000,000,000 on August 6, 2025. The transaction will include participation from new investors SA Value Up No. 3 Fund for KRW 5,000,000,000 and MG Value Up No. 3 Fund for KRW 3,000,000,000. The transaction has been approved by shareholders, expected to close on September 5, 2025, restricted to a hold period, bears 2% coupon rate, 6% maturity rate and matures on September 5, 2028, 100% convertible into 521,308 shares at a fixed conversion price of KRW 15,346 from September 03, 2026 to August 3, 2028. Ankündigung • Aug 01
JS Link, Inc. announced that it has received KRW 5.00000141 billion in funding from B & P Joosung Corp., Joosung Sea & Air Co. Ltd and other investors On July 31, 2025, JS Link, Inc. closed the transaction, Ankündigung • Jul 23
JS Link, Inc. announced that it expects to receive KRW 20.0000056 billion in funding JS Link, Inc. announced a private placement to issue 1,742,768 common shares at an issue price of KRW 11,476 for gross proceeds of KRW 20,000,005,568 on July 21, 2025. The transaction will include participation from new investor Park Jin-soo. The transaction has been approved by shareholders, restricted to a hold period and expected to close on October 31, 2025. New Risk • Apr 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Ankündigung • Apr 17
JS Link, Inc. announced that it has received KRW 10.00000107 billion in funding from Joosung Sea & Air Co. Ltd and other investors On April 16, 2025 JS Link, Inc. closed the transaction. Ankündigung • Mar 27
DNA Link, Inc. announced that it expects to receive KRW 5.00000141 billion in funding DNA Link, Inc. announced a private placement to issue 810,373 common shares at an issue price of KRW 6,170 per share for gross proceeds of KRW 5,000,001,410 on March 26, 2025. The transaction will include participation from returning individual investor Park Jinsu. The transaction has been approved by shareholders, expected to close on July 31, 2025, restricted to a hold period. Reported Earnings • Mar 22
Full year 2024 earnings released: ₩542 loss per share (vs ₩323 loss in FY 2023) Full year 2024 results: ₩542 loss per share (further deteriorated from ₩323 loss in FY 2023). Revenue: ₩15.9b (down 28% from FY 2023). Net loss: ₩10.8b (loss widened 93% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Ankündigung • Mar 13
DNA Link, Inc., Annual General Meeting, Mar 26, 2025 DNA Link, Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 31, magokjungang 8-ro 3-gil, gangseo-gu, seoul South Korea Ankündigung • Jan 17
DNA Link, Inc. announced that it has received KRW 3 billion in funding On January 15, 2025, the company has closed the transaction. New Risk • Jan 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩130.9b market cap, or US$89.6m). Ankündigung • Dec 20
DNA Link, Inc. announced that it expects to receive KRW 10.00000107 billion in funding from Joosung Sea & Air Co. Ltd DNA Link, Inc. announced a private placement to issue 2,594,034 commons shares at an issue price of KRW 3,855 per share for the gross proceeds of KRW 10,000,001,070 on December 19, 2024. The transaction will include participation from new investor Joosung Sea & Air Co. Ltd. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on April 30, 2025. New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩94.3b market cap, or US$65.6m). New Risk • Dec 07
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩95.9b market cap, or US$67.4m). New Risk • Nov 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩92.2b market cap, or US$66.1m). Ankündigung • Jul 31
Entermedia Co.,Ltd. and Lee Jong Eun agreed to acquire 40% stake in National Bitumen Corporation from DNA Link, Inc. (KOSDAQ:A127120) for KRW 7.8 billion. Entermedia Co.,Ltd. and Lee Jong Eun agreed to acquire 40% stake in National Bitumen Corporation from DNA Link, Inc. (KOSDAQ:A127120) for KRW 7.8 billion on July 30, 2024. the consideration is in the form of 7th convertible bond of Orbitech held by the buyers. transaction is expected to complete on July 30, 2024. New Risk • Jun 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Minor Risks Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Market cap is less than US$100m (₩48.0b market cap, or US$34.9m). Reported Earnings • Mar 22
Full year 2023 earnings released: ₩323 loss per share (vs ₩460 loss in FY 2022) Full year 2023 results: ₩323 loss per share (improved from ₩460 loss in FY 2022). Revenue: ₩21.9b (up 29% from FY 2022). Net loss: ₩5.60b (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Ankündigung • Jan 25
DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd. On January 25, 2024, DNA Link, Inc. closed the transaction. Ankündigung • Jan 22
DNA Link, Inc. announced that it expects to receive KRW 2 billion in funding from Orbitech Co., Ltd. DNA Link, Inc. announces private placement of series 10 Domestic bearer interest-unsecured private placement convertible bonds for a principal amount of KRW 2,000,000,000 on January 22, 2024. The bonds will bear a surface interest rate of 2% and interest rate to maturity of 4% and will mature on January 25, 2027. The bonds will convertible into 617,283 shares of the company at conversion price of KRW 3,240 per share at a 100% conversion rate. The transaction will include participation from returning investor, Orbitech Co., Ltd. New Risk • Nov 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.1b free cash flow). Earnings have declined by 5.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Market cap is less than US$100m (₩71.4b market cap, or US$55.0m). New Risk • Sep 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.1b free cash flow). Earnings have declined by 5.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩64.1b market cap, or US$48.4m). Reported Earnings • Apr 01
Full year 2022 earnings released: ₩460 loss per share (vs ₩311 loss in FY 2021) Full year 2022 results: ₩460 loss per share (further deteriorated from ₩311 loss in FY 2021). Revenue: ₩17.0b (down 26% from FY 2021). Net loss: ₩7.78b (loss widened 53% from FY 2021). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Feb 17
New 90-day low: ₩6,530 The company is down 56% from its price of ₩14,850 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. Is New 90 Day High Low • Jan 27
New 90-day low: ₩7,280 The company is down 67% from its price of ₩21,750 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: ₩7,740 The company is down 71% from its price of ₩26,600 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: ₩12,000 The company is down 42% from its price of ₩20,700 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. Ankündigung • Nov 27
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test act the Point of Care BASE10 Genetics and DNA Link announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings; Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available. Is New 90 Day High Low • Nov 16
New 90-day low: ₩14,000 The company is down 21% from its price of ₩17,700 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Oct 08
New 90-day high: ₩24,700 The company is up 267% from its price of ₩6,730 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. 